Claims for Patent: 5,470,829

Summary for Patent: 5,470,829

Title:	Pharmaceutical preparation
Abstract:	Pharmaceutical compositions which release the active ingredient slowly are based upon a growth factor or hormone as active ingredient and a means for effecting slow release of the active ingredient. Means for effecting slow release of the active ingredient comprise a conjugate or mixture of a first component and a second component. The first component is a protein other than the active ingredient for binding growth factors and hormones, and the second component is a biodegradable carrier.
Inventor(s):	Prisell; Per (S-116 50 Stockholm, SE), Norstedt; Gunnar (S-116 42 Bromma, SE)
Assignee:
Application Number:	08/037,124
Patent Claims:	1. In a method for administering ligand selected from the group consisting of growth factors and hormones to an animal comprising administering said ligand in combination with an adjuvant which controls the release of said ligand, said adjuvant comprising a biodegradable polymer and a receptor for said ligand, wherein said receptor is conjugated to a biodegradable polymer, the improvement wherein said receptor comprises (1) a protein for binding said ligand, said protein being selected from the group consisting of insulin-like growth factor-1-receptor; erythropoietin-receptor; insulin-like growth factor-2-receptor; insulin-receptor; platelet derived growth factor-receptor; fibroblast growth factor-receptor; colony stimulating growth factor-receptor; transforming growth factor-receptor; growth hormone-receptor; parathyroid hormone-receptor; calcitonin-receptor; estrogen-receptor; insulin-like growth factor serum binding protein; epidermal growth factor receptor; corticosteroid binding globulin; and bone morphogenic protein and (2) said biodegradable polymer is selected from the group consisting of alginates; hyaluronic acid and derivatives thereof: polyglycolide; copolymers of glycolide; copolymers of glycolide and L-lactide; copolymers of glycolide and trimethylene carbonate; polylactides; stereo-copolymers of polylactides; poly-L-lactide; poly-DL-lactide; copolymers of L-lactide and DL-lactide; copolymers of polylactide; copolymers of lactide and tetramethylglycolide; copolymers of lactide and trimethylene carbonate; copolymers of lactide and .alpha.-valerolactone; copolymers of lactide and .epsilon.-caprolactone; copolymers of polylactide and polyethylene oxide; copolymers of poly-.beta.-hydroxybutyrate; polyurethanes; methylmethacrylate-N-vinyl pyrrolidone copolymers; and poly-p-dioxanone; said ligand being a ligand specific to said protein and being linked to said protein. 2. The method according to claim 1 wherein said active ingredient is IGF-1. 3. The method according to claim 1 wherein said receptor comprises the extracellular domain of the protein for binding said ligand. 4. The method according to claim 1 wherein the biodegradable polymer is hyaluronic acid. 5. The method according to claim 4 wherein the ligand is IGF-1. 6. A method for administering a pharmaceutical preparation to a patient in need thereof comprising administering to said patient a slow release conjugate comprising as active ingredient a ligand selected from the group consisting of growth factors and hormones in combination with an adjuvant which controls the release of said ligand, said adjuvant selected from the group consisting of receptors for said ligand and binding proteins for said ligand, and a biodegradable polymer as carrier for said slow release conjugate, wherein said biodegradable polymer is selected from the group consisting of alginates; hyaluronic acid and derivatives thereof; polyglycolide; copolymers of glycolide; copolymers of glycolide and L-lactide; copolymers of glycolide and trimethylene carbonate; polylactides; stereo-copolymers of polylactides; poly-L-lactide: poly-DL-lactide; copolymers of L-lactide and DL-lactide; copolymers of polylactide; copolymers of lactide and tetramethylglycolide; copolymers of lactide and trimethylene carbonate; copolymers of lactide and .alpha.-valerolactone; copolymers of lactide and .epsilon.-caprolactone; copolymers of polylactide and polyethylene oxide; copolymers of poly-.beta.-hydroxybutyrate; polyurethanes; methylmethacrylate-N-vinyl pyrrolidone copolymers; and poly-p-dioxanone. 7. The method according to claim 6 wherein said receptor is conjugated to said biodegradable polymer. 8. The method according to claim 6 wherein said ligand is selected from the group consisting of insulin-like growth factor-1; insulin-like growth factor-2; platelet-derived growth factor; epidermal growth factor; erythropoietin; fibroblast growth factor; colony stimulating factor; transforming growth factor; calcitonin; parathyroid hormone; growth hormone; estrogens; bone morphogenic protein; corticosteroids; and insulin. 9. The method according to claim 6 wherein said receptor comprises the extracellular domain of said receptor or said binding protein comprises the extracellular domain of said binding protein.

Details for Patent 5,470,829

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2012-11-28